Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab vs Interferon Beta-1a in Early Active RRMS
NCT00050778Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2002
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Started Dec 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00050778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050778.